Clinical Trial

Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)

Study acronym: OMSAGE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 30, 2024 (before its estimated November 4, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objectives is to evaluate the effect of omega-3 fatty acids in old participants with polyvascular disease on immune parameters and inflammatory mediators at different times. Three modalities of administration of omega-3 will be compared with a placebo (olive oil): predominant EPA (Eicosapentaenoic acid), predominant DHA (doxosahexaenoic acid), and combinaison of both. This study will measure the level of omega3 fatty acids in this population 4 hours after taking, on the 7th day, on the 21th day of administration and 1 month after administration.
Trial Details
NCT Number NCT06666101
Lead Sponsor Université Libre de Bruxelles
Collaborators: University of Mons, Université Catholique de Louvain
Conditions Polyvascular Disease
Enrollment 80 participants
Start Date 2024-11-04
Primary Completion 2025-11-04 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-30